U.K.'s Vernalis, Japan's Asahi Kasei reach second milestone in RA candidate

Japan's Asahi Kasei Pharma and U.K.-based Vernalis reached a second milestone on an undisclosed target for rheumatoid arthritis and other autoimmune diseases, which triggered a £500,000 payment to the British company, according to a press release.

"This collaboration with AKP was initiated in October 2013 and utilizes Vernalis' fragment and structure-based drug discovery platform," Vernalis said in the release. "Overall financial terms of this collaboration have not been disclosed."

- here's the release